Latest News

Glassia (more than) half full: "Bioworld Today" features Kamada as its top-story

Mar. 20, 2017

This week's top- story is about Kamada's GVHD clinical program and other interesting clinical implications of its AAT pipeline.

Kamada Announces Collaboration with Massachusetts General Hospital for Proof of Concept Study Evaluating Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation

Feb. 21, 2017

The conpany announced today a collaboration with Massachusetts General Hospital (MGH) to conduct a proof of concept study evaluating the potential benefit of the Company’s Liquid Alpha-1 Antitrypsin (AAT) on liver preservation.

Upcoming Events

Kamada to participate in 15th Conference of the International Society of Travel Medicine

May. 14-18, 2017 / Barcelona - Spain

the 15th Conference of the International Society of Travel Medicine (CISTM15) on 14-18 May 2017 in Barcelona, Spain, marks a highlight in the history of the International Society of Travel Medicine as it will celebrate its 25th anniversary. the International Society of Travel Medicine have 35,000 members from more than 90 countries. 

Kamada to participate in ATS conference, Washington DC, 2017

May. 19-24, 2017 / Washington DC, USA

The American Thoracic Society improves global health by advancing research, patient care, and public health in pulmonary disease, critical illness, and sleep disorders. Founded in 1905 to combat TB, the ATS has grown to tackle asthma, COPD, lung cancer, sepsis, acute respiratory distress, and sleep apnea, among other diseases.

Past Event

Kamada to participate in 3rd International Research Conference on Alpha-1 Antitrypsin and 6th Alpha-1 Global Patient Congress

Apr. 5-8, 2017 / Lisbon, Portugal

The Alpha-1 global mission is to develop a collaborative global network of Alpha-1 patient leaders, physicians, and researchers, to increase awareness, detection, and access to care for Alphas around the world.